<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03044873</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-015</org_study_id>
    <nct_id>NCT03044873</nct_id>
  </id_info>
  <brief_title>Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin</brief_title>
  <official_title>Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to assess the effect of coadministration of multiple doses of BMS-986165 on the
      systemic exposure of rosuvastatin in healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2, 2017</start_date>
  <completion_date type="Actual">March 27, 2017</completion_date>
  <primary_completion_date type="Actual">March 14, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Maximum observed plasma concentration) of Rosuvastatin.</measure>
    <time_frame>Up to Day 13</time_frame>
    <description>Measured by plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-T) (Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration) of Rosuvastatin.</measure>
    <time_frame>Up to Day 13</time_frame>
    <description>Measured by plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(INF) (Area under the plasma concentration-time curve from time zero extrapolated to infinite time) of Rosuvastatin.</measure>
    <time_frame>Up to Day 13</time_frame>
    <description>Measured by plasma concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Deaths.</measure>
    <time_frame>Up till 30 days after discontinuation</time_frame>
    <description>Measured by investigator assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Serious Adverse Events.</measure>
    <time_frame>Up till 30 days after discontinuation</time_frame>
    <description>Measured by investigator assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Adverse Events.</measure>
    <time_frame>Up till 30 days after discontinuation</time_frame>
    <description>Measured by investigator assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Adverse Events Leading to Discontinuation.</measure>
    <time_frame>Up till 30 days after discontinuation</time_frame>
    <description>Measured by investigator assessment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Autoimmune Diseases</condition>
  <condition>Inflammatory Diseases</condition>
  <arm_group>
    <arm_group_label>BMS 986165 and Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986165</intervention_name>
    <description>Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.</description>
    <arm_group_label>BMS 986165 and Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.</description>
    <arm_group_label>BMS 986165 and Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent

          2. Healthy male and female participants (not of childbearing potential) as determined by
             no clinically significant deviation from normal in medical history, physical exam,
             ECGs, and clinical laboratory determinations

          3. Subjects with body mass index of 18 to 32 kg/m2, inclusive.

          4. Women participants must have documented proof that they are not of childbearing
             potential.

          5. Men who are sexually active with WOCBP must agree to follow instructions for method(s)
             of highly effective contraception for the duration of study treatment(s) plus 5
             half-lives of BMS-986165 (4 days) plus 90 days (duration of sperm turnover) for a
             total of 94 days of post BMS-986165 treatment. In addition, male participants must be
             willing to refrain from sperm donation during this time.

        Exclusion Criteria:

          1. History of allergy to BMS-986165, rosuvastatin, or related compounds, of myalgia or
             rhabdomyolysis while taking rosuvastatin or related compounds or any other drug
             allergy

          2. Any significant acute or chronic medical illness, active TB requiring treatment or
             documented latent TB within the previous 3 years, current or recent gastrointestinal
             disease, current or recent history of nausea, vomiting, constipation or irregular
             bowel movement

          3. History of chronic headaches, syncope, orthostatic instability, or recurrent
             dizziness, biliary disorders, drug-induced acne or rash, fibromyalgia, neutropenia or
             thrombocytopenia

          4. Smokers who currently smoke, recent drug or alcohol abuse, blood transfusion within 4
             weeks of study treatment administration, current skin findings that could interfere
             with the interpretation of study

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Phase I Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/Recalls/</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/pages/investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2017</study_first_submitted>
  <study_first_submitted_qc>February 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2017</study_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

